Cytoplasm-predominant Pten associates with increased region-specific brain tyrosine hydroxylase and dopamine D2 receptors in mouse model with autistic traits by unknown
RESEARCH Open Access
Cytoplasm-predominant Pten associates
with increased region-specific brain
tyrosine hydroxylase and dopamine D2
receptors in mouse model with autistic
traits
Xin He1,2, Stetson Thacker1,2,3, Todd Romigh1,2, Qi Yu1,2, Thomas W. Frazier Jr1,2,3,4,5 and Charis Eng1,2,3,6,7,8,9*
Abstract
Background: Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by
impairment in social communication/interaction and inflexible/repetitive behavior. Several lines of evidence
support genetic factors as a predominant cause of ASD. Among those autism susceptibility genes that have
been identified, the PTEN tumor suppressor gene, initially identified as predisposing to Cowden heritable
cancer syndrome, was found to be mutated in a subset of ASD patients with extreme macrocephaly. However, the
ASD-relevant molecular mechanism mediating the effect of PTEN mutations remains elusive.
Methods: We developed a Pten knock-in murine model to study the effects of Pten germline mutations,
specifically altering subcellular localization, in ASD. Proteins were isolated from the hemispheres of the
male littermates, and Western blots were performed to determine protein expression levels of tyrosine
hydroxylase (TH). Immunohistochemical stains were carried out to validate the localization of TH and dopamine D2
receptors (D2R). PC12 cells ectopically expressing either wild-type or missense mutant PTEN were then compared for
the differences in TH expression.
Results: Mice carrying Pten mutations have high TH and D2R in the striatum and prefrontal cortex. They also have
increased phosphorylation of cAMP response element-binding protein (CREB) and TH. Mechanistically, PTEN
downregulates TH production in PC12 cells via inhibiting the phosphoinositide 3-kinase (PI3K)/CREB signaling
pathway, while PTEN reduces TH phosphorylation via suppressing MAPK pathway. Unlike wild-type PTEN but
similar to the mouse knock-in mutant Pten, three naturally occurring missense mutations of PTEN that we
previously identified in ASD patients, H93R, F241S, and D252G, were not able to suppress TH when overexpressed in
PC12 cells. In addition, two other PTEN missense mutations, C124S (pan phosphatase dead) and G129E (lipid phosphatase
dead), failed to suppress TH when ectopically expressed in PC12 cells.
Conclusions: Our data reveal a non-canonical PTEN-TH pathway in the brain that may work as a core regulator of
dopamine signaling, which when dysfunctional is pathogenic in ASD.
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Background
Autism spectrum disorder (ASD) is a group of neurode-
velopmental disorders characterized by impairments in
social interaction and communication, along with the
presence of inflexible/repetitive behaviors [1]. Although
a strong genetic component to ASD has been confirmed
by behavioral genetic studies, only 10–20 % of cases
have a known genetic etiology [2].
The phosphatase and tensin homologue deleted on
chromosome ten (PTEN) gene encodes a dual-specificity
phosphatase that suppresses the activity of the class
Ia phosphoinositide 3-kinase (PI3K) pathway and the
MAPK pathway [3–5]. Cowden syndrome, an inher-
ited breast and thyroid cancer syndrome, is associated
with germline mutations of the PTEN tumor suppressor
gene on 10q23 [6, 7]. Subsequently, PTEN was shown to
also play an important role in brain development and
plasticity [8, 9]. In Pten conditional knockout mice, Pten
deficiency in brain causes dramatically weakened synaptic
transmission and defects in myelination of axons [10]. We
first identified germline PTENmutations in a subset of pa-
tients with ASD and extreme macrocephaly [11], an ob-
servation that was subsequently confirmed by multiple
independent groups [12–14]. An estimated 7 % of children
with ASD and macrocephaly carry a germline PTEN mu-
tation [12]. Despite the macrocephaly, patients who have
ASD and PTEN mutations have a cortex of normal thick-
ness [15]. They also have an overgrowth of white matter
and deficits in working memory and processing [15].
To provide insight into underlying causes for this dis-
order, we previously developed a germline Pten knock-in
murine model of ASD. The male Ptenm3m4/m3m4 mutant
mice have extreme macrocephaly due to megencephaly
[16]. They also mimic individuals with high-functioning
ASD, displaying increased social motivation, poor bal-
ance, and normal recognition memory [17]. It is intri-
guing that germline mutations of PTEN, which
predispose individuals to specific cancer types, can also
be linked with ASD. Unfortunately, the molecular mech-
anism of PTEN mutation-positive ASD (herein, PTEN-
ASD) remains unknown. Disturbed catecholamine me-
tabolism has been reported in patients with ASD [18].
The urinary dopamine levels are reportedly significantly
lower than those in normal children and are inversely
correlated with the severity of autistic behavior [19].
Variants in the dopamine transporter gene (DAT) and
the dopamine-3-receptor gene (DRD3) are associated
with ASD [20, 21]. Adult mice with conditional Pten
knockout in dopaminergic neurons exhibit elevated
expression of tyrosine hydroxylase, the key enzyme for
dopamine synthesis [22]. Based on the fact that PTEN
deletion enhances survival and function of dopamine
neurons [23], we sought to address the hypothesis that
PTEN works as a key player in the regulation of the
dopaminergic signaling in the brain, potentially through
a non-canonical signaling pathway.
Methods
Murine model study
Ptenm3m4 missense knock-in mutant mice were generated
in our lab and were backcrossed more than ten times onto
a CD1 genetic background [24]. Animals were sacrificed
at 8 weeks to harvest brains. The m3m4 dual Pten muta-
tions are located in exon 7 (Fig. 1a). This exon is a hot
spot for PTEN germline mutations in ASD patients
(for instance, F241S, D252G). All protocols involving
mice were approved by the Institutional Animal Care
and Use Committee (IACUC) at the Cleveland Clinic.
Reagents
Cycloheximide was purchased from Sigma-Aldrich
(St. Louis, MO). The mitogen-activated protein kinase
(MAPK)/ERK kinase (MEK) inhibitor, PD98059, was
purchased from Calbiochem (La Jolla, CA). The PI3K
inhibitor, LY294002, was purchased from Cayman
Chemical (Ann Arbor, MI). The AKT inhibitor, Perifosine
(>99 % pure), was purchased from LC laboratories
(Woburn, MA). PTEN phosphatase inhibitor SF1670
was purchased from Cayman Chemical (Ann Arbor,
MI). Nerve growth factor (NGF 2.5S) was purchased
from Life Technologies (Grand Island, NY).
Cell culture
The PC12 rat pheochromocytoma cell line was pur-
chased from ATCC, where they authenticate by STRS
analysis, and has endogenous wild-type Pten. We chose
PC12 cells because it is one of the standard models for
studying neural organs and, more importantly, to reflect
both the ASD and neoplastic phenotypes seen in those
with PTEN mutations. Mycoplasma contamination is
routinely monitored. PC12 cells were grown in RPMI
supplemented with 2 mM glutamine, 5 % fetal bovine
serum (FBS), and 5 % horse serum. Experiments were
performed on cells passaged no more than ten times.
Generation of stable Tet-Off cell lines
The PC12 Tet-Off cell line was purchased from Clon-
tech (Clontech Laboratories, Inc., Mountain View, CA,
Cat#630906). Stable cell lines with Tet-regulated PTEN
expression were generated as we described previously
[25]. Tet-regulated expression of exogenous PTEN was
confirmed by Western blot analysis on total protein
lysates collected from cells grown in the presence or
absence of Tet. The wild-type (WT) construct was used
as the template to engineer each of the individual muta-
tions (TetPTEN-H93R-FLAG, TetPTENF241S-FLAG,
and TetPTEN-D252G-FLAG) to be tested. Each mutant
was engineered using the QuickChange in vitro site-
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directed mutagenesis system (Stratagene) according to
the manufacturer’s instructions.
Cycloheximide chase study
PC12 cells stably expressing FLAG-tagged WT or mutant
PTEN were incubated with cycloheximide (50 μg/mL) and
were harvested at the indicated time points. Whole
protein lysates were extracted and ran for Western blots
using anti-FLAG antibody for transfected PTEN and
GAPDH antibody as a loading control. Experiments were
performed in triplicate.
Plasmid electroporation
CREB Dominant-Negative Vector Set (including CREB,
K-CREB, CREB133) was purchased from Clontech La-
boratories (Mountain View, CA). For electroporation,
4D-Nucleofector was used according to the protocol
from Lonza.
Western blot
Whole cell lysates were extracted from brain tissues or
PC12 cells by using RIPA buffer. Experiments were
replicated in triplicate. All antibodies were purchased
from Cell Signaling Technology (Beverly, MA) except
tyrosine hydroxylase (TH) antibody, which was obtained
from Abcam (Cambridge, MA).
Immunohistochemistry
Briefly, mouse brains were fixed by intracardiac perfu-
sion with 4 % paraformaldehyde in phosphate-buffered
saline (PBS) and postfixation in the same buffer. Speci-
mens were then embedded in paraffin, and sections
processed for immunohistochemical staining with anti-
body against TH (1:100) or dopamine D2 receptor
(1:50, Biorbyt Ltd, Cambridge, UK). Slides were
scanned at ×20 using a Leica SCN400 slide scanner
(Leica Microsystems Inc., Buffalo Grove, IL). Immuno-
fluorescent staining was carried out with dopamine D2




























Fig. 1 Pten mice have increased TH and P-CREB in the frontal cortex and striatum. a NLS-like region of Pten and the missense mutations
(Pten, indicated in bold) created in the NLS-like region. b Western blotting results show elevated AKT and TH signaling, together with diminished Pten
expression in the cerebral hemisphere of the Ptenm3m4/m3m4 mutant mice. c Coronal section of the forebrain immunolabeled with the antibody against
tyrosine hydroxylase (TH). Note the increased density of the TH-positive fibers in the striatum and frontal cortex of the Ptenm3m4/m3m4 mutant
mice. d Coronal section of the forebrain immunolabeled with the antibody against dopamine D2 receptors (D2R). Images were acquired at
(top) ×5 and (bottom) ×20 magnification. Scale bar for top panels is 200 μm and bottom panels is 50 μm
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receptor, and the slides were imaged at ×20 using a
Leica DMI3000 B.
Results
Ptenm3m4 mutant mice have increased TH in the
prefrontal cortex and striatum
To address whether the TH and dopamine pathway in
the brain plays an important role in ASD, we first ex-
amined the TH protein levels by Western blot in the
cerebrum of male littermates aged 8 weeks (Fig. 1b).
TH was significantly elevated in the mutant cerebrum
(Fig. 1b). A similar trend of increase was also found for
phospho-AKTSer473 (P-AKT) and phospho-THSer31 (P-
TH), whereas Pten protein was significantly dimin-
ished in the mutant mice when compared to the WT
littermates (Fig. 1b).
To validate the region of elevated TH in the Ptenm3m4/
m3m4 mutant mouse brains, we then performed immu-
nohistochemical staining of TH. Elevated TH was mainly
distributed in the prefrontal cortex and striatum (Fig. 1c).
Downstream of increased dopaminergic synthesis from
TH is the dopamine D2 receptor (D2R), which plays
critical roles in cognition. Therefore, we next measured
brain D2R as a surrogate for the dopamine signaling
pathway using immunohistochemistry. Consistent with
the TH data, we found significantly increased D2R in the
striatum and prefrontal cortex of the mutant mice
(Fig. 1d). To further verify and quantify the increase in
D2R expression in mutants, frontal sections of mouse
brain were immunofluorescently stained, showing a sig-
nificant increase in D2R expression in the mutant com-
pared to WT (see Additional file 1: Figure S1). Taken
together, these data suggest that the TH-dopamine-D2R
pathway is upregulated in the striatum and prefrontal
cortex of Ptenm3m4/m3m4 mutant mice.
PTEN suppresses TH expression via inhibition of the PI3K/
CREB pathway
The observation of increased AKT phosphorylation in
the context of upregulation of the TH and dopamine
pathways led to our hypothesis that this unexpected
upregulation of the TH-dopamine pathway may be me-
diated by uncurbed PI3K signaling downstream of the
Pten mutations. To test this hypothesis, we generated
rat pheochromocytoma (PC12) cells that stably over-
express human PTEN under the control of the Tet-Off
promoter, and the expression of TH was analyzed by
Western blot. Ectopic PTEN expression was associated
with decreased P-AKT and TH levels in PC12 cells
(Fig. 2a, lane 2) compared to PC cells in its native state
(Fig. 2a, lane 1). In this experiment, we were surprised to
see that ectopic expression of human WT PTEN was asso-
ciated with decreased phosphorylation of CREB (P-CREB)
(Fig. 2a, right panel). Because CREB is a known regulatory
target for AKT [26], we hypothesized that PI3K-dependent
P-CREB allows TH transcription and hence translation.
To test our hypothesis that PI3K-dependent P-CREB
facilitates TH transcription/translation, we sought to de-
termine the levels of P-AKT, P-CREB, and TH after in-
hibition of the PI3K pathway as well as after stimulation
of the PI3K pathway. If our hypothesis is correct, then
inhibition of PI3K should result in the opposite of our
above observation, i.e., decreased expression of TH, P-
AKT, and P-CREB. We achieved PI3K inhibition via two
different, and standard, approaches: pharmacologic in-
hibition of PI3K by LY294002 and serum starvation.
First, we treated PC12 cells overnight with LY294002
(Fig. 2b, left panel, +). As a PI3K inhibitor, LY294002
was expected, and is observed, to decrease P-AKT ex-
pression (while AKT expression with and without treat-
ment were identical). Notably, LY294002 also resulted in
decreased TH and decreased P-CREB (CREB expression
with and without treatment were similar) (Fig. 2b, left
panel, + vs −). Similarly, serum starvation decreased
P-AKT, as well as P-CREB, and TH (Fig. 2b, middle
panel). We then chose NGF as our upregulator of PI3K
and MAPK as an unrelated mimic of dysfunctioning/non-
functioning PTEN: if our hypothesis remains correct, then
NGF should be seen to increase P-AKT, P-CREB, and TH.
When we exposed PC12 cells to NGF, Western blot in-
deed revealed increased expression of P-AKT, P-CREB,
and TH (Fig. 2b, right panel). Thus, we were able to
confirm that the PI3K pathway is important in medi-
ating P-CREB, leading to transcriptional control of
TH expression, at least in vitro.
To test whether CREB phosphorylation is sufficient to
facilitate TH expression, we transfected PC12 cells with
CREBWT and two different CREB mutant constructs,
CREBS133A and K-CREB (Fig. 2c). CREBS133A is a mutant
in which serine 133, the major phosphorylation site of
CREB, is changed to alanine, thus abrogating its ability
to be phosphorylated. If our hypothesis is correct, then
CREBS133A should be associated with no/little P-CREB
and decreased TH. Expression of the mutant CREBS133A
is, in fact, associated with dramatically decreased P-CREB,
as expected; of note, CREBS133A transfection is also associ-
ated with decreased TH (Fig. 2c, right lane), thus
confirming our hypothesis. K-CREB is a dominant-
negative mutant form of CREB. If our hypothesis is
correct, K-CREB should decrease TH, without affect-
ing P-CREB. Indeed, expression of K-CREB decreased
TH without markedly reducing the P-CREB (Fig. 2c,
middle lane). Of relevance, we identified, via bioinfor-
matic analysis, a CREB consensus binding site at the
5′UTR of the TH gene (Fig. 2d). As partial in vivo
validation of our observations in PC12 cells, we were
able to show elevated CREB phosphorylation in the
cerebrum of the Ptenm3m4/m3m4 mice (Fig. 2e) where
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we have already shown increased TH expression (Fig. 1c).
Taken together, our observations suggest that mutant
PTEN is associated with upregulation of the PI3K path-
way, manifested by increased P-AKT, resulting in CREB
phosphorylation and subsequent increased TH tran-
scription. Said another way, functioning (WT) PTEN
suppresses TH expression via inhibition of the PI3K/
CREB pathway.
Wild-type PTEN reduces the phosphorylation of TH
We have already observed increased TH and increased
phosphorylated TH in the cerebrum of our Pten mutant
mice (above, Fig. 1b). Phosphorylation of TH is already
known to increase TH protein stability and activity
[27, 28]. Thus, we sought to determine if PTEN can
also regulate TH phosphorylation.
PC12 cells at rest have low levels of P-TH (Fig. 3a, left
panel, lane 1). We used NGF to make PC12 cells active;
with only 30 min of NGF treatment, P-TH was significantly
elevated (Fig. 3a, left panel, lane 3). The overexpression of
PTEN (Tet−, i.e., Tet-Off turns on transfected PTEN)
caused decreased P-TH (Fig. 3a, left panel, lane 4
[Tet−, PTEN on] vs lane 2 [Tet+, PTEN off]). After
densitometry normalization, we found that total TH
decreased ~20 % after exogenous PTEN expression,
whereas the P-TH decreased ~50 % after exogenous
PTEN expression (Fig. 3a, right panel). To further
illustrate the effect of PTEN on TH phosphorylation,
we used a PTEN inhibitor called SF1670 to inhibit both
the ectopically expressed PTEN and the endogenously
expressed PTEN in our PC12 cell line. A dramatic in-
crease in phosphorylation at S31 on TH in PC12 cells was
observed after treating for 3 h with the IC50 of SF1670.
Moreover, a modest increase was observed in S40 phos-
phorylation. Consistent with our immunostaining of the
m3m4 mouse brains, an increase in D2R expression was
also observed after inhibition of PTEN with SF1670 (see












































Fig. 2 PTEN suppresses TH expression via inhibition of the PI3K/CREB pathway. a FLAG-tagged wild-type PTEN was expressed (Tet−, i.e., Tet-Off)
or not expressed (Tet+) in PC12 cells, whose lysates were interrogated by Western blot for the labeled proteins/phosphoproteins (left panel).
GAPDH is loading control. Note that FLAG-PTEN expression associates with decreased P-AKT (right lane vs left lane), decreased P-CREB,
and decreased TH. Normalized quantitation of TH and P-CREB in the presence of PTEN overexpression (Tet−) or no PTEN overexpression
(Tet+) (right panel). Note that Tet+ PC12 cells have endogenous rat wild-type Pten. b Western blots for named proteins/P-proteins after
inhibition of PI3K by LY294002 (left panel) or serum starvation (middle panel) and after upregulation of PI3K by brief NGF exposure (right panel). Note
that PI3K inhibition (manifested by increased P-AKT) is associated with decreased phospho-CREB and TH, whereas NGF stimulation of PI3K (manifested
by decreased P-AKT) is associated with increased P-CREB and TH expression. c Western blot for TH, P-CREB, CREB, and GAPDH loading control after
inhibition of CREB phosphorylation by expression of a CREB dominant-negative mutant (K-CREB) and a phosphorylation mutant (CREBS133A) compared
to wild-type CREB (CREBWT). Note decreased TH expression associated with both (inactive) CREB mutants. d Identification of a CREB consensus binding
site at the 5′UTR of the TH gene. e Elevated CREB phosphorylation in the cerebrum from Ptenm3m4/m3m4 mutant mice
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suggest that normal PTEN signaling inhibits TH ex-
pression (see above sections) as well as phosphorylation
of TH.
PTEN can act as both a protein and lipid phosphatase
that inhibits both MAPK and PI3K pathways. We have
already shown (above sections) that PTEN inhibits the
PI3K pathway to decrease CREB phosphorylation and
total TH levels. Now, we would also like to determine if
inhibition of MAPK and/or PI3K would affect TH phos-
phorylation. To minimize the effect of the change on
total TH by chemical inhibitors, we only treated cells for
3 h with either the PI3K inhibitor, LY294002, or the
MAPK inhibitor, PD98059, in media without serum.
After 3 h, PC12 cells were treated with NGF for 30 min
to awaken resting PC12 cells. NGF-stimulated PC12
cells had increased phosphorylation of TH without alter-
ing the level of total TH (Fig. 3b, lane 2). Surprisingly,
PD98059, but not LY294002, inhibited NGF-stimulated
TH phosphorylation in PC12 cells (Fig. 3b, lane 4 vs 6).
Therefore, PTEN appears to suppress the phosphoryl-
ation of TH through inhibition of MAPK, probably
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Fig. 3 PTEN suppresses TH phosphorylation and stability via inhibition of the ERK/MAPK pathway in PC12 cells. a Western blot of the named
proteins/phosphoproteins after exposure of NGF (to activate PC12 cells from resting state) or not, in the presence (Tet−) or absence (Tet+) of
exogenous PTEN expression (left panel). Note that expression of PTEN reduces TH phosphorylation in PC12 cells. Normalized quantitation of relative TH
and P-TH expression in the presence (white bar, Tet−) or absence (black bar, Tet+) of exogenous PTEN expression with (NGF+) or without
(NGF−) exposure (right bar graphs). b Western blot of the named proteins/phosphoproteins in the presence (+) or absence (−) of MAPK
inhibitor PD98059 or of PI3K inhibitor LY294002 with (+) or without (−) NGF stimulation of PC12 cells. Note that MAPK inhibitor PD98059,
but not PI3K inhibitor LY294002, is associated with decreased P-TH even after NGF stimulation
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this, functional PTEN inhibitor SF1670, even in the pres-
ence of PTEN overexpression, resulted in increased P-ERK,
slightly increased TH, and clearly increased P-TH (see
Additional file 1: Figure S2 comprising lane 3 vs lane 2).
Three PTEN missense mutants identified in ASD patients
cannot suppress TH
In order to validate the role of PTEN mutations in
ASD patients, we transfected three naturally occurring
ASD-associated PTEN mutations into PC12 cells to
see if these mutant PTEN constructs can suppress
TH in vitro. If our mouse and PC12 data above are
correct, then these three ASD-associated PTEN germ-
line mutations should not be able to suppress TH levels.
Indeed, all three mutations, H93R, F241S, and D252G,
cannot suppress TH when expressed in PC12 cells. They
also failed to suppress P-AKT (Fig. 4a, left panel). We then
investigated TH expression after expression of PTEN
mutations, C124S which is pan phosphatase dead and
G129E which is only lipid phosphatase dead. Next, we
investigated TH phosphorylation when these mutants
were expressed in the presence of PTEN inhibitor SF1670.
The three different PTEN mutations varied in their abil-
ity to suppress TH phosphorylation at S31 and S40;
however, the general trend was an inability to suppress
phosphorylation of TH as effectively as WT PTEN (see
Additional file 1: Figure S3). Expression of both PTEN
mutants in PC12 cells could not suppress P-AKT, TH,
or P-TH (Fig. 4a, right panel). Again, our results under-
score that the intact lipid phosphatase activity is neces-
sary for PTEN to decrease TH expression, while intact
protein phosphatase activity is necessary for PTEN to
inhibit TH phosphorylation.
Diminished protein stability in ASD-associated PTEN
missense mutations
Based on our observations that the Ptenm3m4/m3m4 mutant
mice have diminished Pten protein levels in the brain [17],
we hypothesized that ASD-associated PTEN mutations
decrease the stability of PTEN protein. We therefore in-
terrogated PTEN protein stability through a cyclohexi-
mide chase study (Fig. 4b). The WT PTEN protein was
stable after synthesis and we observed that its levels re-































































Fig. 4 ASD-derived PTEN mutants fail to inhibit TH in vitro. a Left panel, loss of inhibitory effect of ASD-derived PTEN mutants on TH; PC12 cells
stably expressed different PTENs were cultured in media with (Tet+) or without tetracycline (Tet−) [19]. TH was then measured by Western blot;
right panel, tumor-associated PTEN mutants cannot inhibit TH. PC12 cells were transiently transfected with either vector or C124S and G129E mutant
PTEN, and TH was measured by Western blot. b Cycloheximide chase reveals decreased protein stability of the ASD-derived PTEN mutants.
c PTEN-induced molecular mechanism mediating the dopamine synthesis in the brain. PTEN suppresses NGF-induced activation of PI3K and
ERK-MAPK pathways. PI3K phosphorylates CREB at Ser133 and further increases the transcription and translation of the TH gene. ERK-MAPK
phosphorylates TH at Ser31 and increases the stability of the TH protein. Hyperactivity of both pathways caused by PTEN mutations leads to
upregulated TH/dopamine synthesis and triggers the expression of the D2R receptors in neural tissue
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In contrast, H93R, F241S, and D252G and m3m4 PTEN/
Pten mutant proteins are highly unstable. More than
50 % of the mutant m3m4 and D252G PTEN proteins
were degraded after 8 h of cycloheximide treatment.
For H93R and F241S, more than 80 % of the mutant
PTEN protein was degraded after 8 h of cyclohexi-
mide treatment (Fig. 4b).
Discussion
The present study demonstrates the increased expres-
sion and phosphorylation of TH in the prefrontal cortex
and striatum of a Pten knock-in ASD mouse model. Our
data indicate that functioning PTEN suppresses TH tran-
scription through the inhibitory effect on PI3K and
P-CREB, whereas PTEN also inhibits TH phosphoryl-
ation through suppressing the MAPK pathway (Fig. 4c).
Thus, PTEN inhibits TH-dopamine pathway through its
role as dual protein and lipid phosphatase.
Dopamine plays a key role in the regulation of loco-
motion, learning, behavior, emotion, and social inter-
action. TH is the rate-limiting enzyme in the synthesis of
dopamine. Therefore, it is reasonable to posit that dysreg-
ulation of the dopaminergic system is linked to the patho-
physiology of ASD. Of relevance, we have shown that
mutations of the PTEN gene augment TH synthesis and
function, and this may lead to the release of too much
dopamine in the prefrontal cortex and midbrain, which
can result in repetitive and obsessive behaviors. This can
also explain the motor disorders (such as poor balance)
reported in our mouse model [17]. Intriguingly, several
groups have reported dysregulated dopamine function in
ASD patients. Cartier et al. reported that two rare variants
in STX1A and SLC6A3 that associate with autism disrupt
reverse transport of dopamine [29]. This same group also
found that another variant of SLC6A3, the dopamine
transporter gene, caused alterations in dopamine transport
function and trafficking, which associated with ASD in
two different families [30]. A Japanese group found that
dopamine transporter binding was significantly higher in
the orbitofrontal cortex of autistic individuals [31].
Furthermore, dysfunction of Pten has been associated with
potential disruption of dopamine function and ASD be-
haviors in other mouse models. Conditional knockout of
Pten in dopaminergic neurons resulted in neuronal hyper-
trophy, an increased number of dopaminergic neurons
and fibers in the ventral mesencephalon, and social behav-
ioral impairments [32, 33]. It has also been demonstrated
that a germline Pten haploinsufficient model has altered
social behavior, mirroring the social deficits of ASD, and
displays neuronal overgrowth driven by β-catenin signal-
ing [34, 35]. If the activated TH-dopamine pathway is ger-
mane to PTEN-ASD, there is a possibility that these
symptoms could be reversed with pharmaceuticals that
target the PTEN-TH-dopamine pathway.
The D2R represents the main autoreceptor of the
dopaminergic system in the brain. The upregulation of
striatal D2R expression is a notable finding in our study.
A role for D2R in ASD susceptibility is suggested by the
fact that risperidone, which prevents D2R activation, can
reduce disruptive behavior in about half of the children
with ASD [36]. In humans, D2R is encoded by the
DRD2 gene, which is a language-related gene. Variants
in the DRD2 gene, especially the rs1800498TT genotype
and the A1 allele of the Taq I polymorphism, have been
found to influence language traits in children with ASD
[37–39]. Further studies of the effects of D2R on ASD
will be required in order to assess whether common
mechanisms are shared with what are reported herein
for PTEN-mediated inhibitory effects on the dopamine
pathway.
As a dual lipid and protein phosphatase, PTEN can
suppress both the PI3K and the MAPK signaling path-
ways. We show that PTEN inhibits TH transcription by
suppressing the PI3K and CREB pathways. We also
show that PTEN can also suppress TH phosphorylation
through its protein phosphatase activity by inhibiting
ERK-MAPK. Thus, both lipid and protein phosphatase
activities of PTEN are involved in TH regulation. The
ASD-associated mutations of PTEN may present a “double
whammy” in leading to ASD. Not only does PTEN signal-
ing lessen total TH but it also reduces the phosphorylation
of TH that leads to decreased activity and stability of TH
protein. By using three ASD-associated PTEN missense
mutations (H93R, F241S, D252G), we demonstrate the loss
of PTEN’s inhibitory effects on P-AKT and TH and show
that the lipid phosphatase activity of PTEN plays a major
role in TH inhibition. Indeed, TH gene transcription is
tightly controlled by the PTEN-PI3K pathway, as reported
previously [40].
Conclusions
Our observations reveal a novel inhibitory role of PTEN
in the regulation of dopamine signaling via the non-
canonical PTEN-TH-dopamine pathway in neural tissue.
Mutations of the PTEN gene can enhance TH in two
ways: the loss of the lipid phosphatase activity of PTEN
will induce TH transcription and translation through the
dysregulated PI3K/CREB pathway and the loss of the
protein phosphatase activity of PTEN will enhance the
phosphorylation of TH through the MAPK pathway.
Continued investigation of the PTEN-TH-dopamine
pathway in ASD will uncover novel drug targets for ex-
ploitation by new therapeutic interventions.
Availability of supporting data
Supplementary information is available at Molecular
Psychiatry’s website.
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Additional files
Additional file 1: Supplementary Information. Three supplementary
figures comprising Figure S1A. Immunofluorescent staining of frontal
sections of mouse brains indicates increased D2R expression and larger
nuclei in Ptenm3m4/m3m4 mice. Figure S1B. Quantification of D2R
immunofluorescence in triplicates of each genotype’s frontal section
of mouse brains indicates the mutant D2R immunofluorescence is
significantly increased in comparison to the immunofluorescence in
the wild-type (P = 0.021). Figure S2. Inhibition of ectopic and endogenous
PTEN function with SF1670 leads to an increase in phosphorylation of TH in
PC12 cells. PTEN inhibitor is applied in lanes 1 and 3 (+) but off in lane 2 (−).
Tetracycline is on (+) in lane 1, turning off ectopic expression of wild-type
PTEN in PC12 cells that has endogenous wild-type PTEN. Tet-Off (−) turns
on ectopic expression of wild-type human PTEN (lanes 2 and 3). Figure S3.
Overexpression of naturally occurring ASD-associated germline PTEN
mutations are unable to completely suppress TH phosphorylation. When
tetracycline is applied (Tet+), ectopic PTEN expression is turned off. When
tetracycline is removed (Tet-Off; −), ectopic expression of PTEN occurs. (PDF
965 kb)
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